 | Up a level |
Juillerat, Pascal; Sokol, Harry; Froehlich, Florian; Yajnik, Vijay; Beaugerie, Laurent; Lucci, Matthew; Burnand, Bernard; Macpherson, Andrew; Cosnes, Jacques; Korzenik, Joshua R. (2015). Factors Associated with Durable Response to Infliximab in Crohnʼs Disease 5 Years and Beyond: A Multicenter International Cohort. Inflammatory bowel diseases, 21(1), pp. 60-70. Lippincott Williams & Wilkins 10.1097/MIB.0000000000000225
Juillerat, Pascal; Wasan, Sharmeel K.; Fowler, Sharyle A.; Friedman, Sonia; Pabby, Vikas K.; Coukas, Jennifer A.; Barto, Amy E.; Pellish, Randall; Germansky, Katharine A.; Cheifetz, Adam S.; Korzenik, Joshua R.; Farraye, Francis A.; Yajnik, Vijay (2013). Efficacy and Safety of Natalizumab in Crohn’s Disease Patients Treated at 6 Boston Academic Hospitals. Inflammatory bowel diseases, 19(11), pp. 2457-2463. Lippincott Williams & Wilkins 10.1097/MIB.0b013e3182a32a0d
Juillerat, Pascal; Sokol, Harry; Fowler, Sharyle A.; Froehlich, Florian; Vader, John-Paul; Yajnik, Vijay; Beaugerie, Laurent; Macpherson, Andrew J.; Cosnes, Jacques; Korzenik, Joshua R. (2013). 950 Factors associated with durable response to infliximab 5 years and beyond: a multi center international cohort. Gastroenterology, 144(5, Suppl. 1), p. 172. Elsevier
Juillerat, Pascal; Fowler, Sharyle; Yajnik, Vijay; R.Korzenik, Joshua (2012). CHARACTERISTICS OF PATIENTS WITH DURABLE USE OF INFLIXIMAB FOR > 5 YEARS. Gut, 2012 London: BMJ Publishing Group
Juillerat, Pascal; Fowler, Sharyle; Yajnik, Vijay; R.Korzenik, Joshua (2012). CHARACTERISTICS OF PATIENTS WITH DURABLE USE OF INFLIXIMAB FOR > 5 YEARS. Schweizerisches Medizin-Forum SMF / Swiss medical forum / Forum médical suisse FMS, 2012 Basel: EMH Editores Medicorum Helveticorum
